Cancer organoids with breast cancer 2 genes, EGFR, and EGFR‐mutant/MSC‐epithelial transition (MET)‐amplified mutations responded better to laparib, erlotinib, and crizotinib, respectively.181. This evidence concerns the gene EGFR and breast carcinoma.